Finance

Lists
Why is CTNM up 8.06%?
Dive Deeper
CTNM:NASDAQ
Contineum Therapeutics Inc
$9.52
+8.06%
(+0.71) 1D
Nov 6, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CTNM...
Open
$8.96
High
$9.79
Low
$8.59
Mkt. cap
373.81M
Avg. vol.
1.14M
Volume
343.54K
52-wk high
$17.78
52-wk low
$6.72
EPS
-$1.77
Shares outstanding
35.35M
No. of employees
51
Open
$8.96
High
$9.79
Low
$8.59
Mkt. cap
373.81M
Avg. vol.
1.14M
Volume
343.54K
52-wk high
$17.78
52-wk low
$6.72
EPS
-$1.77
Shares outstanding
35.35M
No. of employees
51
News stories
From web sources and news partners
About Contineum Therapeutics Inc
CEO-
Employees51
Founded2009
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websitecontineum-tx.com
Analyst ratings
Based on 8 analysts giving stock ratings to CTNM in the past 3 months
Strong buy
Buy
6
Hold
2
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for CTNM in the last 3 months.
Highest
Current $9.52
$30.00 (+215.13%)
Average
$22.14 (+132.56%)
Lowest
$14.00 (+47.06%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brian Abrahams
RBC Capital
Buy
Maintained
$21.00
+120.6%
11/03/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
$30.00
+215.1%
11/03/2026
Charles Moore
Robert W. Baird
Hold
Downgraded
$14.00
+47.1%
10/14/2026
Sean Laaman
Morgan Stanley
Hold
Maintained
$17.00
+78.6%
10/12/2026
Paul Matteis
Stifel Nicolaus
Buy
Reiterated
$28.00
+194.1%
10/12/2026
Myles Minter
William Blair
Buy
Maintained
-
-
09/30/2026
Gaurav Maini
LifeSci Capital
Buy
Maintained
$23.00
+141.6%
09/29/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
$22.00
+131.1%
09/16/2026
Last report
Nov 3, 2026
Fiscal period
Q3 2026
-$0.49 / -$0.45
-8.20%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
12.00M
11.14M
11.97M
15.26M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.12M
5.76M
5.45M
5.70M
Operating expense
17.12M
16.90M
17.43M
20.97M
Total operating expenses
17.12M
16.90M
17.43M
20.97M
Operating income
-17.12M
-16.90M
-17.43M
-20.97M
Other non operating income
-51.00K
-57.00K
-68.00K
-93.00K
EBT including unusual items
-15.16M
-14.46M
-15.15M
-18.70M
EBT excluding unusual items
-15.16M
-14.46M
-15.15M
-18.70M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-15.16M
-14.46M
-15.15M
-18.70M
Net profit margin
-
-
-
-
Earnings per share
-0.49
-0.39
-0.40
-0.49
Interest and investment income
2.01M
2.50M
2.34M
2.36M
Interest expense
-
-
-
-
Net interest expenses
2.01M
2.50M
2.34M
2.36M
Depreciation and amortization charges
-
-
-
-
EBITDA
-17.03M
-16.82M
-17.29M
-20.88M
Gain or loss from assets sale
-
2.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps